You Position: Home > Paper

Diagnosis and treatment progress of primary light-chain amyloidosis

( views:0, downloads:0 )
Author:
No author available
Journal Title:
Journal of Leukemia and Lymphoma
Issue:
1
DOI:
10.3760/cma.j.cn115356-20221228-00363
Key Word:
原发性轻链型淀粉样变;诊断;治疗;Primary light-chain amyloidosis;Diagnosis;Treatment

Abstract´╝Ü Primary light-chain (AL) amyloidosis is a rare and fatal plasma cell disease. In recent years, the treatment of AL amyloidosis has changed from the era of bortezomib to the era of daratumumab immunotherapy. However, for the treatment choice of advanced-staged patients, how to achieve organ responses at the early stage and how to monitor the disease are questions that need to be further explored. The 64th American Society of Hematology Annual Meeting in 2022 has reported advances in the diagnosis and treatment of AL amyloidosis, which are briefly reviewed in this article.

  • This article has no references!
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn